![Proffered paper 2_ELCC 2023](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-2023/proffered-paper-2_elcc-2023/17554205-1-eng-GB/proffered-paper-2_elcc-2023_i770.jpg)
Long-term event-free survival benefits of neoadjuvant nivolumab plus chemotherapy for resectable NSCLC
Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker